PA
DPLO

Parallel Advisors’s DIPLOMAT PHARMACY, INC. DPLO Stock Holding History

Parallel Advisors’s Portfolio DPLO Stock Details DPLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-276
Closed -$1K – 2561
2019
Q3 		$1K Buy
+276
New +$1.54K ﹤0.01% 2371

Other funds holding DPLO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Stephens Inc Little Rock, Arkansas $7.99B AUM 21.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Parallel Advisors's DPLO Position: Q4 2019 in Review

Parallel Advisors sold out of DIPLOMAT PHARMACY, INC. (DPLO) in Q4 2019, closing a stake of 276 shares — an estimated $1K sold.

Parallel Advisors first reported a position in DPLO in Q3 2019 and held it in 1 quarter. The position peaked at $1K in Q3 2019. 138 funds tracked by Wall St. Rank hold DPLO as of Q4 2019.

  • Parallel Advisors reported no remaining DIPLOMAT PHARMACY, INC. position as of Q4 2019 after selling out during the quarter.
  • Parallel Advisors sold 276 DIPLOMAT PHARMACY, INC. shares in Q4 2019, an estimated $1K.
  • Parallel Advisors first reported a position in DIPLOMAT PHARMACY, INC. in Q3 2019 and held it in 1 quarter.
  • Parallel Advisors's DIPLOMAT PHARMACY, INC. position peaked at $1K in Q3 2019.
  • 138 funds tracked by Wall St. Rank held DIPLOMAT PHARMACY, INC. as of Q4 2019.

Based on Parallel Advisors's 13F filing for Q4 2019, filed 30 Jan 2020.